Foster City, CA, United States of America

Kapil Kumar Karki

This inventor holds 13 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Gilead Sciences, Inc., Cypralis Limited, Selcia Limited. Active years: 2015-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kapil Kumar Karki. Retrieved from https://idiyas.com/inventor/kapil-kumar-karki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 4)

% Patents Active = 61.5

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 16.5

ph-index = 3

Forward Citations = 25(Granted Patents)

Company Filing History:

11 out of 946

Gilead Sciences, Inc.

Gilead Pharmasset LLC

patents

where one patent can have more than one assignee

Years Active: 2015-2020

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10603318 - Inhibitors of hepatitis C virus (2020-03-31),

2. 10335409 - Inhibitors of hepatitis C virus (2019-07-02),

3. RE47334 - Macrocyclic inhibitors of flaviviridae viruses (2019-04-01),

4. 10246486 - Macrocyclic inhibitors of flaviviridae viruses (2019-04-02),

5. 10030033 - Synthesis of an antiviral compound (2018-07-24),

6. 9873716 - Macrocyclic inhibitors of flaviviridae viruses (2018-01-23),

7. 9655944 - Inhibitors of hepatitis C virus (2017-05-23),

8. 9617310 - Inhibitors of hepatitis C virus (2017-04-11),

9. 9512175 - Macrocyclic inhibitors of flaviviridae viruses (2016-12-06),

10. 9440991 - Synthesis of an antiviral compound (2016-09-13),

11. 9296782 - Inhibitors of hepatitis C virus (2016-03-29),

12. 9145441 - Macrocyclic inhibitors of flaviviridae viruses (2015-09-29),

13. 9090653 - Macrocyclic inhibitors of flaviviridae viruses (2015-07-28),

Title: The Innovator Extraordinaire: Kapil Kumar Karki

Introduction

Meet Kapil Kumar Karki, an esteemed inventor based in Foster City, California. With a remarkable portfolio comprising 13 patents, Kapil is a visionary in the field of pharmaceutical innovation.

Latest Patents

His latest patents revolve around the development of groundbreaking inhibitors for the hepatitis C virus. These compounds, along with their pharmaceutically acceptable salts, are detailed in Formula I. Furthermore, Kapil has elucidated methods for utilizing these compounds and integrating them into pharmaceutical compositions.

Career Highlights

Kapil Kumar Karki has made significant contributions to the pharmaceutical industry through his work with renowned companies such as Gilead Sciences, Inc. and Selcia Limited. His expertise and dedication have led to the creation of impactful solutions that address pressing healthcare challenges.

Collaborations

During his illustrious career, Kapil has collaborated with exceptional professionals in the field. Noteworthy among them are his peers Adam James Schrier and Dustin S Siegel. Together, they have synergized their talents to drive innovation and deliver cutting-edge pharmaceutical solutions.

Conclusion

In conclusion, Kapil Kumar Karki stands as a trailblazer in the realm of pharmaceutical inventions. His relentless pursuit of excellence and commitment to advancing healthcare make him a true luminary in the industry. With a rich tapestry of patents and collaborations, Kapil continues to shape the landscape of pharmaceutical innovation for the betterment of society.

Profile summary based on public USPTO records.